Abstract
The use of G-CSF and GM-CSF has been shown to benefit patients undergoing autologous hematopoietic SCT (HSCT), mainly after autologous bone marrow transplantation. Their benefit in allogeneic transplant is not as pronounced and the use of growth factors in this patient group remains controversial due to conflicting reports of whether the use of growth factors increases the incidence of acute and chronic GvHD. The efficacy of EPO in HSCT patients is not well studied, but a reduction in the number of RBC transfusions has been shown in patients undergoing allogeneic transplant. Also the efficacy of thrombopoietic agents to date has not been demonstrated. One promising new approach to reduce the degree of mucositis is the use of recombinant keratinocyte growth factor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
American Society of Clinical Oncology. American society of clinical oncology recommendations for the use of hematopoietic colony stimulating factors: evidence based clinical practice guidelines. J Clin Oncol 1994; 12: 2471–2508.
American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1996; 14: 1957–1960.
Bennett CL, Smith TJ, Weeks JC, Bredt AB, Feinglass J, Fetting JH et al. Use of hematopoietic colony stimulating factors: The American society of clinical oncology survey. J Clin Oncol 1996; 14: 2511–2520.
Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ . Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American society of clinical oncology surveys regarding ASCO clinical practice guidelines. J Clin Oncol 1999; 17: 3676–3681.
Ozer H, Armitage J, Bennet CL . 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol 2000; 20: 3558–3585.
Boogaerts M, Cavalli F, Cortés-Funes H, Gatell JM, Gianni AM, Khayat D et al. Granulocyte growth factors: achieving a concensus. Ann Oncol 1995; 6: 237–244.
Schaison G, Eden OB, Henze G, Kamps WA, Locatelli F, Ninane J et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Ped 1998; 157: 955–966.
Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR . Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22: 3350–3356.
Armitage JO . Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 4491–4508.
Lieschke G, Burgess A . Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992; 327: 99–106.
Suzue T, Takaue Y, Watanabe A, Kawano Y, Watanabe T, Abe T et al. Effects of rhG-CSF on the recovery of hematopoyesis alter high-dose chemotherapy and autologous peripheral blood item cell transplantation in children: A Report from the Children's Cancer and Leukemia Study Group of Japan. Exp Hematol 1994; 2: 1197–1202.
González-Vicent M, Madero L, Sevilla J, Ramirez M, DÃaz MA . A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell transplantation in children. Bone Marrow Transplant 2004; 34: 1077–1081.
Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C et al. Granulocyte clony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84: 1680–1684.
Saarinen UM, Hovi L, Juvonen E, Riikonen P, Möttönen M, Mäkipernaa A . Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children. Med Ped Oncol 1996; 26: 380–386.
Madero L, DÃaz MA, Ortega JJ, Olive T, MartÃnez A, Badell I et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics alter allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Hematologica 1999; 84: 133–137.
Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Löffler H et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666–1672.
Ringdén O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the acute leukemia working party of the European Group for blood and marrow transplantation. J Clin Oncol 2004; 22: 416–423.
Kobayashi S, Imamura M, Hashino S, Noto S, Mori A, Tanaka J et al. Possible role of granulocyte colony-stimulating factor in increased serum soluble interleukin-2 receptor-alpha levels after allogeneic bone marrow transplantation. Leuk Lymphoma 1999; 33: 559–566.
Dallorso S, Rondelli R, Messina C, Pession A, Giorgiani G, Fagioli F et al. Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial. Haematologica 2002; 87: 1274–1280.
Ho VT, Mirza NQ, del Junco D, Okamura T, Przepiorka D . The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 2003; 32: 771–775.
Locatelli F, Rocha V, Chastang C, Arcese W, Michel G, Abecasis M et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-cord blood transplant group. Blood 1999; 93: 3662–3671.
Cairo MS, Wagner JE . Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 1997; 90: 4665–4678.
Klaesson S, Ringdén O, Ljungman P, Lönnqvist B, Wennberg L . Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994; 13: 397–402.
Locatelli F, Zecca M, Pedrazzoli P, Prete L, Quaglini S, Comoli P et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994; 13: 403–410.
Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M et al. The effects of pegylated recombinant human megakaryocyte growth and development factor on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 2002; 30: 1044–1050.
Seggewiss R, Loré K, Guenaga FJ, Pittaluga S, Mattapallil J, Chow CK et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood 2007; 110: 441–449.
Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005; 35: 1165–1169.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Conflict of interest
The author declared no financial interests.
Rights and permissions
About this article
Cite this article
Badell, I., on behalf of the EBMT Paediatric Working Party. Cytokines following SCT: indications and controversies. Bone Marrow Transplant 41 (Suppl 2), S27–S29 (2008). https://doi.org/10.1038/bmt.2008.50
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.50